Augustine Therapeutics will present a late-breaking poster at the American Diabetes Association 86th Scientific Sessions in New Orleans on 7 June 2026, during the late-breaking poster session (Poster 3067-LB, 12:30 PM to 1:30 PM CT) in Poster Hall D-E.
The presentation will feature in vivo efficacy results from a preclinical mouse model of heart failure with preserved ejection fraction for one of Augustine’s HDAC6 inhibitor development candidates.
Augustine is a biotechnology company developing selective HDAC6 inhibitors for cardiometabolic, neuromuscular and neurodegenerative diseases, and the company claims its non-hydroxamate, non-hydrazide chemotype is designed to be selective and suitable for chronic diseases.
The release notes Augustine completed an oversubscribed EUR 78 million Series A financing in March 2025 led by Novo Holdings and Jeito Capital. According to the company, the poster will be uploaded to Augustine’s website after the presentation.
